Determination of the ROS1 gene mutation from a biopsy of tumor tissue by immunohistochemical method

Immunohistochemistry (IHC) is a method of localization of specific antigens in tissues based on the recognition of an antigen by an appropriate antibody and the detection of the results of this binding at the light–optical level. It is an additional research method, carried out after histological confirmation of the diagnosis of malignant neoplasm.

The method was first described in the 1940s, when Coons and co-authors developed the immunofluorescence technique for detecting antigens in frozen slices. Since then, the method has been improved and today this method occupies key positions in oncology, helping in the diagnosis of a malignant tumor, selection and evaluation of the effectiveness of drug treatment of patients.

IGH Goals:

to carry out histogenetic diagnosis of tumors;
to determine the nosological variant of the neoplasm;
to identify a primary tumor by metastasis with an unknown primary focus;
to determine the prognosis of a tumor disease;
to determine the malignant transformation of cells;
identify the possibilities of targeted therapy;
to identify both resistance and sensitivity of tumor cells to chemotherapeutic drugs;
to determine the sensitivity of tumor cells to radiation therapy.

Immunohistochemical analysis of breast formations (HER-2/neu, progesterone, estrogen and KI-67 receptors):

Her-2/neu - determines the sensitivity of the tumor to antitumor drugs;
ki -67 is a marker of tumor activity;
progesterone and estrogen receptors – sensitivity to hormones (hormone therapy) Biomaterial – histological blocks (paraffin blocks) with glass preparations.